In 2021, Utah had the highest rate of skin cancer, with an estimated 46 people out of 100,000 diagnosed with melanoma or another non-epithelial skin cancer. This statistic shows the incidence rate of skin cancer in the U.S. in 2021, by state, per 100,000 population.

It was predicted that in 2025 there would be a total of 104,960 new melanoma skin cancer cases in the United States, of which 11,140 would occur in California. This statistic shows the estimated number of new cases of melanoma of the skin in the U.S. in 2025, by state.

In 2021, Idaho had the highest death rate from skin cancer, with an estimated 2.8 people out of 100,000 dying from melanoma. This statistic shows the death rate for melanoma of the skin in the U.S. in 2021, by state, per 100,000 population.

As of 2021, non-Hispanic white people in the United States had the highest incidence rates of skin cancer among all races and ethnicities. Skin cancer is one of the most commonly occurring cancers in the world. Furthermore, the United States is among the countries with the highest rates of skin cancer worldwide. Skin cancer in the U.S. There are a few different types of skin cancer and some are more deadly than others. Basal and squamous skin cancers are more common and less dangerous than melanomas. Among U.S. residents, skin cancer has been demonstrated to be more prevalent among men than women. Skin cancer is also more prevalent among older adults. With treatment and early detection, skin cancers have a high survival rate. Fortunately, in recent years the U.S. has seen a reduction in the rate of death from melanoma. Skin cancer prevention Avoiding and protecting exposed skin from the sun (and other sources of UV light) is the primary means of preventing skin cancer. However, a survey of U.S. adults from 2024 found that around a third never used sunscreen.

In 2022, Australia had the fourth-highest total number of skin cancer cases worldwide and the highest age-standardized rate, with roughly 37 cases of skin cancer per 100,000 population. The graph illustrates the rate of skin cancer in the countries with the highest skin cancer rates worldwide in 2022.

The rate of skin cancer in the United States increased for both sexes from 1999 to 2021, with the rate for males consistently higher than that of females. This statistic shows the incidence rate of skin cancer in the U.S. from 1999 to 2021, by gender, per 100,000 population.

Market Overview:

The 7 major nonmelanoma skin cancer markets reached a value of US$ 467.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 621.3 Million by 2034, exhibiting a growth rate (CAGR) of 2.62% during 2024-2034.

Report Attribute	Key Statistics
Base Year	2023
Forecast Years	2024-2034
Historical Years	2018-2023
Market Size in 2023	US$ 467.4 Million
Market Forecast in 2034	US$ 621.3 Million
Market Growth Rate (2024-2034)	2.62%

The nonmelanoma skin cancer market has been comprehensively analyzed in IMARC's new report titled "Nonmelanoma Skin Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Nonmelanoma skin cancer refers to a group of skin cancers that develop from the basal cells or squamous cells of the skin, excluding melanocytes. The most common symptom is the formation of an abnormal growth or lesion on the skin that may vary in size, shape, color, or texture over time. Basal cell carcinoma (BCC), the most prevalent type of nonmelanoma skin cancer, include symptoms like small, shiny, or raised bumps, pink/red patches, and non-healing sores that might bleed or crust. Squamous cell carcinoma (SCC), the second most common disease type, often appears as scaly, red/pink elevated growths that may develop a crust or ulcerate. The diagnostic process usually begins with a thorough examination of the skin, focusing on any suspicious lesions. The healthcare provider will assess the characteristics of the lesion, such as its size, shape, texture, etc. If a suspicious area is identified, skin biopsy can be performed. Various additional procedures, including imaging scans and sentinel lymph node biopsy, are also recommended in some instances to determine the extent of the cancer.

https://www.imarcgroup.com/CKEditor/f3513b55-cb8e-4079-a5ac-4541ea27a319nonmelanoma-skin-cancer-market-report-(1).webp" style="height:450px; width:800px" />

The increasing cases of prolonged exposure to UV radiation that lead to abnormal cell growth and the development of cancerous lesions are primarily driving the nonmelanoma skin cancer market. Besides this, the rising prevalence of several associated risk factors, including weakened immune system, chronic skin inflammation, family history, use of indoor tanning beds or sunlamps, etc., is acting as another significant growth-inducing factor. Furthermore, the escalating usage of Mohs micrographic surgery for treating large, aggressive, or recurrent cancererous cells or those located in cosmetically sensitive areas is also bolstering the market growth. Additionally, the emerging popularity of cryosurgery, which involves freezing nonmelanoma skin cancer cells with liquid nitrogen, is creating a positive outlook for the market. The freezing destroys the abnormal cells, leading to their sloughing off and subsequent healing. Moreover, the inflating demand for immune checkpoint inhibitors, such as pembrolizumab and nivolumab, to enhance the body's immune response against malignant cells is also augmenting the market growth. Apart from this, the increasing application of electronic brachytherapy for treating lesions since it minimizes damage to surrounding tissues, thereby preserving aesthetics and resulting in better cosmetic outcomes compared to other invasive procedures, is expected to drive the nonmelanoma skin cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the nonmelanoma skin cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for nonmelanoma skin cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the nonmelanoma skin cancer market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
  

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the nonmelanoma skin cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the nonmelanoma skin cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current nonmelanoma skin cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Drugs	Company Name
Keytruda (Pembrolizumab)	Merck & Co
Libtayo (Cemiplimab)	Regeneron Pharmaceuticals
Bavencio (Avelumab)	Avelumab
EscharEx	MediWound
AIV001	AiViva BioPharma
STP705	Sirnaomics
Patidegib	Sol-Gel Technologies
LTX315	Lytix Biopharma

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the nonmelanoma skin cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the nonmelanoma skin cancer market across the seven major markets in 2023 and what will it look like in 2034?
<li

This publication reports on newly diagnosed cancers registered in England in addition to cancer deaths registered in England during 2020. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document.

This dataset presents the footprint of cancer incidence data in Australia for all cancers combined, and six selected cancers (female breast cancer, colorectal cancer, cervical cancer, lung cancer, melanoma of the skin, and prostate cancer) with their respective ICD-10 codes. The data spans the years 2009 to 2013 and is aggregated to the 2015 Primary Health Network (PHN) geographic areas based on the 2011 Australian Statistical Geography Standard (ASGS).

The source of the incidence data is the 2014 Australian Cancer Database (ACD). The ACD is compiled by the Australian Institute of Health and Wellbeing (AIHW) from data provided by the state and territory population-based cancer registries. For further information about this dataset, please visit:

• AIHW - Cancer Incidence and Mortality in Australia Data Tables

• 2014 Australian Cancer Database Data Quality Statement

Please note:

• AURIN has spatially enabled the original data using the Department of Health - PHN Areas.

• Where records are null, data was not publishable because of small numbers, confidentiality or other concerns about the quality of the data.

In 2021, the death rate due to melanoma of the skin in the United States was two per 100,000 population. The maximum rate in the given period was 2.8 per 100,000 population. This statistic shows the death rate of melanoma of the skin in the United States from 1999 to 2021.

In 2021, around 13,883 people aged 70 to 74 years were diagnosed with melanoma of the skin or another non-epithelial skin cancer, the highest number of any age group. This statistic shows the number of new skin cancer cases in the U.S. in 2021, by age.

Rate: Number of deaths due melanoma cancer per 100,000 Population.

Definition: Number of deaths per 100,000 with malignant melanoma of the skin as the underlying cause of death (ICD-10 code: C43).

Data Sources:

(1) Centers for Disease Control and Prevention, National Center for Health Statistics. Compressed Mortality File. CDC WONDER On-line Database accessed at http://wonder.cdc.gov/cmf-icd10.html

(2) Death Certificate Database, Office of Vital Statistics and Registry, New Jersey Department of Health

(3) Population Estimates, State Data Center, New Jersey Department of Labor and Workforce Development

Melanoma cases of Washington reduced by 1.12% from 2,680 number in 2023 to 2,650 number in 2024. Since the 0.36% increase in 2020, melanoma cases slumped by 5.36% in 2024.

Detailed summaries on predicting and classifying skin cancer in other studies.

Melanoma cases of South Carolina leapt by 7.22% from 1,800 number in 2023 to 1,930 number in 2024.

Melanoma cases of Georgia climb by 4.83% from 3,310 number in 2023 to 3,470 number in 2024. Since the 4.21% decrease in 2022, melanoma cases dipped by 4.67% in 2024.

This dataset, released September 2017, contains data on the female cancer incidences during 2006-2010 by Breast cancer, Colorectal Cancer, Melanoma of the skin, Lung cancer, Uterine cancer, Lymphoma cancer, Leukaemia cancer, Thyroid cancer, Ovarian cancer, Pancreatic cancer, All other cancers and All cancers combined. The data is by Primary Health Network (PHN) 2017 geographic boundaries based on the 2016 Australian Statistical Geography Standard (ASGS).

There are 31 PHNs set up by the Australian Government. Each network is controlled by a board of medical professionals and advised by a clinical council and community advisory committee. The boundaries of the PHNs closely align with the Local Hospital Networks where possible.

For more information please see the data source notes on the data.

Source: Compiled by PHIDU from an analysis by the Australian Institute of Health and Welfare (AIHW) of the Australian Cancer Database (ACD) 2015. The ACD is compiled at the AIHW from cancer data provided by state and territory cancer registries: for further information on the ACD see link. AURIN has spatially enabled the original data. Data that was not shown/not applicable/not published/not available for the specific area ('#', '..', '^', 'np, 'n.a.', 'n.y.a.' in original PHIDU data) was removed.It has been replaced by by Blank cells. For other keys and abbreviations refer to PHIDU Keys.

It was estimated that in 2025, around 60,550 men in the United States would develop melanoma of the skin, while 44,410 women would develop the disease. This statistic depicts the estimated number of new skin cancer cases in the U.S. in 2025, by gender.

BackgroundMalignant melanoma is the most lethal form of skin cancer which shows BRAF mutation in 50% of patients. In this context, the identification of BRAFV600E mutation led to the development of specific inhibitors like PLX4032. Nevertheless, although its initial success, its clinical efficacy is reduced after six-months of therapy leading to cancer relapse due to the onset of drug resistance. Therefore, investigating the mechanisms underlying PLX4032 resistance is fundamental to improve therapy efficacy. In this context, several models of PLX4032 resistance have been developed, but the discrepancy between in vitro and in vivo results often limits their clinical translation.MethodsThe herein reported model has been realized by treating with PLX4032, for six months, patient-derived BRAF-mutated melanoma cells in order to obtain a reliable model of acquired PLX4032 resistance that could be predictive of patient’s treatment responses. Metabolic analyses were performed by evaluating glucose consumption, ATP synthesis, oxygen consumption rate, P/O ratio, ATP/AMP ratio, lactate release, lactate dehydrogenase activity, NAD+/NADH ratio and pyruvate dehydrogenase activity in parental and drug resistant melanoma cells. The intracellular oxidative state was analyzed in terms of reactive oxygen species production, glutathione levels and NADPH/NADP+ ratio. In addition, a principal component analysis was conducted in order to identify the variables responsible for the acquisition of targeted therapy resistance.ResultsCollectively, our results demonstrate, for the first time in patient-derived melanoma cells, that the rewiring of oxidative phosphorylation and the maintenance of pyruvate dehydrogenase activity and of high glutathione levels contribute to trigger the onset of PLX4032 resistance.ConclusionTherefore, it is possible to hypothesize that inhibitors of glutathione biosynthesis and/or pyruvate dehydrogenase activity could be used in combination with PLX4032 to overcome drug resistance of BRAF-mutated melanoma patients. However, the identification of new adjuvant targets related to drug-induced metabolic reprogramming could be crucial to counteract the failure of targeted therapy in metastatic melanoma.

This dataset, released September 2017, contains data on the total cancer incidences during 2006-2010 by Colorectal Cancer, Melanoma of the skin, Lung cancer, Lymphoma cancer, Leukaemia cancer, Pancreatic cancer, and All cancers combined. The data is by Local Government Area (LGA) 2016 geographic boundaries. For more information please see the data source notes on the data. Source: Compiled by PHIDU from an analysis by the Australian Institute of Health and Welfare (AIHW) of theAustralian Cancer Database (ACD) 2012. The ACD is compiled at the AIHW from cancer data provided by state andterritory cancer registries. AURIN has spatially enabled the original data. Data that was not shown/not applicable/not published/not available for the specific area ('#', '..', '^', 'np, 'n.a.', 'n.y.a.' in original PHIDU data) was removed.It has been replaced by by Blank cells. For other keys and abbreviations refer to PHIDU Keys.